Evidence map›Paper›PMID 41280939›Full record

ArticleFrontiers in immunology2025

A dual-modality machine learning precision diagnostic model integrated radiomics and proteomics for breast cancer.

Pengping Li, Yuan Liu, Ren Liu, Yuqin Huang, Ke Sun, Kexin Yin, Jiajia Lu, Lanqing Li, Shuirong Zhang, Claire Y Tong and 3 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Pengping Li *The First People's Hospital of Xiaoshan District, Xiaoshan Affiliated Hospital of Wenzhou Medical University, Hangzhou, China.
Yuan Liu *The First People's Hospital of Xiaoshan District, Xiaoshan Affiliated Hospital of Wenzhou Medical University, Hangzhou, China.
Ren Liu *The First People's Hospital of Xiaoshan District, Xiaoshan Affiliated Hospital of Wenzhou Medical University, Hangzhou, China.
Yuqin HuangThe First People's Hospital of Xiaoshan District, Xiaoshan Affiliated Hospital of Wenzhou Medical University, Hangzhou, China.
Ke SunThe First People's Hospital of Xiaoshan District, Xiaoshan Affiliated Hospital of Wenzhou Medical University, Hangzhou, China.
Kexin YinThe First People's Hospital of Xiaoshan District, Xiaoshan Affiliated Hospital of Wenzhou Medical University, Hangzhou, China.
Jiajia LuThe First People's Hospital of Xiaoshan District, Xiaoshan Affiliated Hospital of Wenzhou Medical University, Hangzhou, China.
Lanqing LiHangzhou Cosmos Wisdom Mass Spectrometry Center of Zhejiang University Medical School, Hangzhou, China.
Shuirong ZhangHangzhou Cosmos Wisdom Mass Spectrometry Center of Zhejiang University Medical School, Hangzhou, China.
Claire Y TongPhillips Academy Andover, Boston, MA, United States.
Jiayi LiuSalisbury School, Salisbury, MD, United States.
Junli GaoHangzhou Cosmos Wisdom Mass Spectrometry Center of Zhejiang University Medical School, Hangzhou, China.
Zhenyu WangThe First People's Hospital of Xiaoshan District, Xiaoshan Affiliated Hospital of Wenzhou Medical University, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This study aims to construct a dual-modal machine learning model that integrates ultrasound radiomics and plasma proteomics for the precise diagnosis of breast cancer. Methods: Using a multi-source data integration strategy, 10 protein markers and 14 ultrasound radiomics features were screened from the TCGA, CPTAC databases, and the clinical cohort (including 60 healthy controls, 60 cases of benign breast diseases, and 60 cases of breast cancer) based on plasma protein mass spectrometry and ultrasound data. A dual-modal diagnostic model was constructed in combination with machine learning algorithms. Results: The results showed that the protein marker detection model performed outstandingly in the primary screening of healthy people and breast diseases (with the highest AUC of 0.974). Still, its diagnostic performance was limited in differentiating benign and malignant diseases (AUC<0.8 under multiple algorithms). The bimodal model demonstrated excellent performance (AUC = 0.938) in differentiating benign and malignant lesions, significantly outperforming the single proteomics model (AUC = 0.830) and the radiomics model (AUC = 0.841). Conclusion: This study confirmed for the synergistic diagnostic value of plasma proteins and ultrasound images, providing a new strategy with both accuracy and accessibility for stratified diagnosis of breast cancer.

Indexed as

Biomarkers, TumorBreast NeoplasmsMachine LearningProteomicsAdultAlgorithmsBlood ProteinsFemaleHumansMiddle AgedRadiomicsUltrasonography, MammaryBiomarkers, TumorBlood Proteinsbreast cancerdiagnosis modelmachine learningproteomicsradiomics

Identifiers

PMID41280939
PMCPMC12629940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.